Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A International Multicenter, Randomized, Double-Blind, Controlled Phase II/III Study to Evaluate the Efficacy and Safety of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

NCT06548347 is registered in ClinicalTrials.gov with Shanghai YingLi Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT06548347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06548347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A International Multicenter, Randomized, Double-Blind, Controlled Phase II/III Study to Evaluate the Efficacy and Safety of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
Lead sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
September 10, 2024
Completion date
September 30, 2029
Enrollment
606 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t cell lymphoma